Quality-adjusted Time Without Symptoms of Disease Progression or Toxicity (Q-Twist) of Nivolumab Plus Cabozantinib (N+C) Versus Sunitinib (SUN) in Treatment-Naïve, Advanced/metastatic Renal Cell Carcinoma (arcc): A Post-Hoc Analysis of CheckMate 9ER (CM 9ER) Data.
Journal of clinical oncology（2021）
Abstract
6567 Background: In CM 9ER (ClinicalTrial.gov identifier NCT03141177), N+C demonstrated significant progression-free survival gains (median: 17.0 vs. 8.3 months [mos]; hazard ratio [HR]: 0.52; P
MoreTranslated text
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined